EMN 2021 | CARTITUDE-1: cilta-cel improves HRQoL for patients with myeloma
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, shares an update on health-related quality-of-life (HRQoL) data from the Phase Ib/II CARTITUDE-1 study (NCT03548207) investigating ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), in patients with relapsed/refractory multiple myeloma. Analysis found that patients with relapsed/refractory multiple myeloma showed rapid and clinically meaningful improvements in HRQoL after receiving a cilta-cel infusion. It was also found that HRQoL improved with increased depth of response. This interview took place during the 2021 European Myeloma Network (EMN) congress.
Disclosures
Thomas Martin, MD, recieves research funding to his institution from Sanofi, AMGEN, Janssen
